WO2021020788A2 - 2-((6-(히드록시메틸)크로멘-5-일)옥시)-1-페닐에타논 유도체의 합성 방법 - Google Patents
2-((6-(히드록시메틸)크로멘-5-일)옥시)-1-페닐에타논 유도체의 합성 방법 Download PDFInfo
- Publication number
- WO2021020788A2 WO2021020788A2 PCT/KR2020/009549 KR2020009549W WO2021020788A2 WO 2021020788 A2 WO2021020788 A2 WO 2021020788A2 KR 2020009549 W KR2020009549 W KR 2020009549W WO 2021020788 A2 WO2021020788 A2 WO 2021020788A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- nmr
- cdcl
- formula
- Prior art date
Links
- 0 C[C@@]1C(C=C(C*)C(CBr)=O)=*1 Chemical compound C[C@@]1C(C=C(C*)C(CBr)=O)=*1 0.000 description 9
- UATCGWZQUPRBGV-UHFFFAOYSA-N CC(C)(CC1)Oc2c1c(OCC(c(c(OCc1ccccc1)c1)ccc1OCCOC)=O)c(CO)cc2 Chemical compound CC(C)(CC1)Oc2c1c(OCC(c(c(OCc1ccccc1)c1)ccc1OCCOC)=O)c(CO)cc2 UATCGWZQUPRBGV-UHFFFAOYSA-N 0.000 description 1
- NUVPILSUFJMBFG-UHFFFAOYSA-N CC(C)(CCC12)OC1=CC(OC)=C(CO)C2O Chemical compound CC(C)(CCC12)OC1=CC(OC)=C(CO)C2O NUVPILSUFJMBFG-UHFFFAOYSA-N 0.000 description 1
- CYDNFGLWWYAWAL-UHFFFAOYSA-N CC(C)C(CC=C1C(COc2c(CO)ccc3c2CCC(C)(C)O3)=O)C=C1OCc1ccccc1 Chemical compound CC(C)C(CC=C1C(COc2c(CO)ccc3c2CCC(C)(C)O3)=O)C=C1OCc1ccccc1 CYDNFGLWWYAWAL-UHFFFAOYSA-N 0.000 description 1
- XPERAXPYORKVSW-UHFFFAOYSA-N CC(C1CO)C=C2OC(C)(C)CCC2=C1O Chemical compound CC(C1CO)C=C2OC(C)(C)CCC2=C1O XPERAXPYORKVSW-UHFFFAOYSA-N 0.000 description 1
- XXLNQXUGNBNBMA-UHFFFAOYSA-N CC1(C)Oc2ccc(CO)c(OC=C=O)c2C=C1 Chemical compound CC1(C)Oc2ccc(CO)c(OC=C=O)c2C=C1 XXLNQXUGNBNBMA-UHFFFAOYSA-N 0.000 description 1
- VYRNSMJYXWVAOD-UHFFFAOYSA-N CCC1=CCC(C(COC2=C(C=CC(C)(C)O3)C3=CC(C)C2CO)=O)C(OCc2ccccc2)=C1 Chemical compound CCC1=CCC(C(COC2=C(C=CC(C)(C)O3)C3=CC(C)C2CO)=O)C(OCc2ccccc2)=C1 VYRNSMJYXWVAOD-UHFFFAOYSA-N 0.000 description 1
- NRJWRNYPEDFCNN-UHFFFAOYSA-N CCCC1=CCC(C(COC2=C(C=CC(C)(C)O3)C3=CC(C)C2CO)=O)C(OCc2ccc(C)cc2)=C1 Chemical compound CCCC1=CCC(C(COC2=C(C=CC(C)(C)O3)C3=CC(C)C2CO)=O)C(OCc2ccc(C)cc2)=C1 NRJWRNYPEDFCNN-UHFFFAOYSA-N 0.000 description 1
- WGSFEWHAKLFVBG-UHFFFAOYSA-N CCCCOc1cc(OC)c(C)cc1 Chemical compound CCCCOc1cc(OC)c(C)cc1 WGSFEWHAKLFVBG-UHFFFAOYSA-N 0.000 description 1
- VNAAQXHVAYXVEM-UHFFFAOYSA-N CCCOc1ccc(C(COC(C2CO)=C3C=CC(C)(C)OC3CC2OC)O)c(OCc2ccccc2)c1 Chemical compound CCCOc1ccc(C(COC(C2CO)=C3C=CC(C)(C)OC3CC2OC)O)c(OCc2ccccc2)c1 VNAAQXHVAYXVEM-UHFFFAOYSA-N 0.000 description 1
- JKOFQDODWFGYII-UHFFFAOYSA-N CCCc1ccc(C(COc2c(CCC(C)(C)O3)c3ccc2CO)=O)c(OCC2=CC=CCC2N=O)c1 Chemical compound CCCc1ccc(C(COc2c(CCC(C)(C)O3)c3ccc2CO)=O)c(OCC2=CC=CCC2N=O)c1 JKOFQDODWFGYII-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
Definitions
- the present invention relates to a method for synthesizing 2-((6-(hydroxymethyl)chromen-5-yl)oxy)-1-phenylethanone derivatives.
- Patent Document 1 Korean Patent Publication No. 10-2015-0075030 discloses that pyranochromenylphenol derivatives are effective in preventing and treating various metabolic syndromes including hyperlipidemia, fatty liver, abnormal glucose metabolism, diabetes and obesity.
- Patent Document 2 [Korean Patent Publication No. 10-2018-0037584] is a key intermediate for synthesizing these pyranochromenylphenol derivatives. 3-phenyl-2,3,4,8,9,10-hexahydro A method for preparing a pyrano[2,3-f]chromene derivative is disclosed.
- Patent Document 2 a compound of Formula A-1 and a compound of Formula A-2 are coupled as shown in Scheme A below to obtain a compound of Formula A-3, and reduction to obtain a compound of Formula A-4 And, a method of synthesizing various derivatives disclosed in Patent Document 1 through a cyclization reaction to obtain a compound of Formula A-5 and finally hydrogenation is disclosed.
- the step of preparing the compound of formula A-4 from the compound of formula A-3 not only does the reaction proceed by slowly adding L-selectride ® at -78 °C, which is a cryogenic temperature, but also because L-selectride ® is expensive. 2 represented by a-4 - ((6- (hydroxymethyl) -2 H - chromen-5-yl) oxy) to commercially mass-produced for a heptanone derivative to 1-phenyl considerable labor and is difficult to follow I can.
- the technical problem to be achieved by the present invention is to provide a synthetic method capable of mass-producing 2-((6-(hydroxymethyl)chromen-5-yl)oxy)-1-phenylethanone derivatives under mild conditions.
- An exemplary embodiment of the present invention comprises the steps of (a) reducing the compound of formula 1 to prepare a compound of formula 2; And (b) 2-((6-(hydroxymethyl)chromen-5-yl)oxy)-1- represented by Chemical Formula 4 comprising the step of coupling the compound of Chemical Formula 2 with the compound of Chemical Formula 3 Methods for the synthesis of phenylethanone derivatives are provided:
- Dotted line is an optional double bond
- R 1 and R 2 are each independently a hydrogen atom; A substituted or unsubstituted, straight or branched C 1 -C 6 alkyl group; Halogen atom; A substituted or unsubstituted, straight or branched C 1 -C 6 alkoxy group; A substituted or unsubstituted, straight or branched C 1 -C 4 thioalkyl group; A substituted or unsubstituted allyloxy group; Substituted or unsubstituted aryloxy group; And a phenyl group;
- R 3 is a hydrogen atom; C 1 -C 3 alkyl group; C 1 -C 3 alkoxy group; And a halogen atom;
- R 4 and R 5 are each independently a hydrogen atom; Or a C 1 -C 2 alkyl group;
- P is a substituted or unsubstituted, straight or branched C 1 -C 4 alkyl group; A substituted or unsubstituted benzyl group; Allyl group; t-butyldimethylsilyl group; t-butyldiphenylsilyl group; Dimethylphenylsilyl group; Trimethylsilyl group; MeSO 2 ; p-toluenesulfonyl group; And 2,4,6-trimethylbenzenesulfonyl group;
- n 1 to 3;
- the substituent is a benzyloxy group, a halogen atom, a straight or branched C 1 -C 5 alkyl group, a straight chain Or a branched C 1 -C 5 alkoxy group, a straight or branched C 1 -C 3 thioalkyl group, a nitro group and a naphthalene group.
- Another exemplary embodiment of the present invention includes the steps of (i) cyclizing a compound of Formula 4 prepared according to an exemplary embodiment of the present invention to prepare a compound of Formula 5; And (ii) 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3- f ]chromene derivative of formula I comprising the step of reducing the compound of formula 5 Provides a way to synthesize:
- the dotted line is an optional double bond
- R 1 to R 5 , P and n are the same as defined in Formulas 1 to 4.
- Another exemplary embodiment of the present invention provides a 6-(hydroxymethyl)chromen-5-ol derivative or a solvate thereof represented by the following Formula 2:
- R 3 is a hydrogen atom; C 1 -C 3 alkyl group; C 1 -C 3 alkoxy group; And a halogen atom;
- R 4 and R 5 are each independently a hydrogen atom; Or C 1 -C 2 alkyl group.
- the production method according to an exemplary embodiment of the present invention is a simple, commercially easy to produce 2-((6-(hydroxymethyl)chromen-5-yl)oxy)-1-phenylethanone derivative. .
- the production method according to an exemplary embodiment of the present invention can economically produce 2-((6-(hydroxymethyl)chromen-5-yl)oxy)-1-phenylethanone derivative.
- An exemplary embodiment of the present invention comprises the steps of (a) reducing the compound of formula 1 to prepare a compound of formula 2; And (b) 2-((6-(hydroxymethyl)chromen-5-yl)oxy)-1- represented by Chemical Formula 4 comprising the step of coupling the compound of Chemical Formula 2 with the compound of Chemical Formula 3 Methods for the synthesis of phenylethanone derivatives are provided:
- Dotted line is an optional double bond
- R 1 and R 2 are each independently a hydrogen atom; A substituted or unsubstituted, straight or branched C 1 -C 6 alkyl group; Halogen atom; A substituted or unsubstituted, straight or branched C 1 -C 6 alkoxy group; A substituted or unsubstituted, straight or branched C 1 -C 4 thioalkyl group; A substituted or unsubstituted allyloxy group; Substituted or unsubstituted aryloxy group; And a phenyl group;
- R 3 is a hydrogen atom; C 1 -C 3 alkyl group; C 1 -C 3 alkoxy group; And a halogen atom;
- R 4 and R 5 are each independently a hydrogen atom; Or a C 1 -C 2 alkyl group;
- P is a substituted or unsubstituted, straight or branched C 1 -C 4 alkyl group; A substituted or unsubstituted benzyl group; Allyl group; t-butyldimethylsilyl group; t-butyldiphenylsilyl group; Dimethylphenylsilyl group; Trimethylsilyl group; MeSO 2 ; p-toluenesulfonyl group; And 2,4,6-trimethylbenzenesulfonyl group;
- n 1 to 3;
- the substituent is a benzyloxy group, a halogen atom, a straight or branched C 1 -C 5 alkyl group, a straight chain Or a branched C 1 -C 5 alkoxy group; It is any one of a linear or branched C 1 -C 3 thioalkyl group, a nitro group and a naphthalene group.
- Examples of the 2-((6-(hydroxymethyl)chromen-5-yl)oxy)-1-phenylethanone derivative represented by Chemical Formula 4 include the following compounds.
- Step (a) is a step of preparing a compound of Formula 2 by reducing the formyl group (-COH) of the compound of Formula 1.
- the reduction may be performed at 0° C. to 5° C. using a reducing agent, for example, sodium borohydride, lithium aluminum hydride, diisobutyl aluminum hydride, or the like.
- the reducing agent may be sodium borohydride or lithium aluminum hydride.
- the step of reducing the compound of Formula A-3 to the compound of Formula A-4 in Patent Document 2 requires selective reduction of only the formyl group without reducing the carbonyl group of the ketone.
- the synthetic method of the present invention can easily prepare the compound of formula 4 without using a reaction selective reducing agent under mild conditions by first reducing the compound of formula 1.
- step (b) may be performed under basic conditions.
- step (b) may be performed using a basic compound.
- the basic condition is sodium hydroxide (NaOH), potassium hydroxide (KOH), sodium carbonate (Na 2 CO 3 ), lithium carbonate (Li 2 CO 3 ), potassium carbonate (K 2 CO 3 ) , Sodium hydrogen carbonate (NaHCO 3 ), potassium hydrogen carbonate (KHCO 3 ), triethylamine, and pyridine may be added to one or more basic compounds selected from, and specifically, potassium carbonate or sodium carbonate.
- Another exemplary embodiment of the present invention includes the steps of: (i) cyclizing the compound of Formula 4 prepared according to an exemplary embodiment of the present invention to prepare a compound of Formula 5; And (ii) 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3- f ]chromene derivative of formula I comprising the step of reducing the compound of formula 5 Provides a way to synthesize:
- the dotted line is an optional double bond
- R 1 to R 5 , P and n are the same as defined in Formulas 1 to 4.
- Step (ii) may be to reduce the double bond in the compound of Formula 5 and to remove the protecting group to synthesize the compound of Formula I.
- the removal of the protecting group may be performed through a hydrogenation reaction using Pd/C (palladium on carbon), which is the same as the reaction for reducing the double bond, as a catalyst.
- Another embodiment of the present invention provides a 6-(hydroxymethyl)chromen-5-ol derivative or a solvate thereof represented by the following Formula 2:
- R 3 is a hydrogen atom; C 1 -C 3 alkyl group; C 1 -C 3 alkoxy group; And a halogen atom;
- R 4 and R 5 are each independently a hydrogen atom; Or C 1 -C 2 alkyl group.
- Examples of the 6-(hydroxymethyl)chromen-5-ol derivative represented by Formula 2 include the following compounds.
- 2-((6-(hydroxymethyl)chromen-5-yl)oxy)-1-phenylethanone derivatives are simple, commercially, and economically economical under mild conditions. Can be manufactured.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
화학구조 | NMR | |
실시예 1 | 1H-NMR (CDCl 3) : 8.063(d, 1H, J=8.8Hz), 7.35~7.32(m, 5H), 7.001(d, 1H, J=8.4Hz), 6.585(dd, 1H, J=8.8, 2.0Hz), 6.532(d, 1H, J=8.0Hz), 6.503(d, 1H, J=2.0Hz), 6.383(d, 1H, J=10Hz), 5.464(d, 1H, J=9.6Hz), 5.092(s, 2H), 5.065(s, 2H), 4.522(s, 2H), 4.078(q, 2H, J=13.6), 3.502(br, 1H), 1.424(t, 3H, J=6.8Hz), 1.367(s, 6H) | |
13C-NMR (CDCl 3) : 194.136, 164.785, 160.506, 154.276, 153.734, 135.384, 133.298, 130.280, 129.713, 128.772, 128.570, 127.905, 126.120, 117.735, 117.273, 114.343, 112.067, 106.684, 99.536, 80.734, 75.497, 70.927, 63.988, 61.479, 27.543, 14.594 | ||
실시예 2 | 1H-NMR (CDCl 3) : 8.047(d, 1H, J=8.8Hz), 7.375~7.279(m, 5H), 6.574(dd, 1H, J=9.2, 2.4Hz), 6.495(d, 1H, J=2.4Hz), 6.479(s, 1H), 6.330(d, 1H, J=10Hz), 5.405(d, 1H, J=9.6Hz), 5.120(s, 2H), 5.078(s, 2H), 4.618(d, 2H, J=6.4Hz), 4.126~4.044(m, 2H), 3.156(br, 1H), 2.325(s, 3H), 1.417(t, 3H, J=7.2Hz), 1.359(s, 6H) | |
13C-NMR (CDCl 3) : 192.848, 164.723, 160.478, 154.581, 153.075, 139.010, 135.408, 133.229, 130.478, 129.135, 128.710, 128.665, 128.507, 127.920, 124.442, 117.383, 114.026, 111.674, 81.044, 75.421, 63.952, 56.773, 27.547, 19.331, 14.574 | ||
실시예 3 | 1H-NMR (CDCl 3) : 8.048(d, 1H, J=8.8Hz), 7.386~7.296(m, 5H), 6.567(dd, 1H, J=8.8, 2Hz), 6.509(s, 1H), 6.369(d, 1H, J=10Hz), 6.207(s, 1H), 5.348(d, 1H, J=10Hz), 5.120(s, 2H), 5.088(s, 2H), 4.637(d, 2H, J=6.8Hz), 4.060(q, 2H, J=14, 7.2Hz), 3.799(s, 3H), 3.032(t, 1H, J=6.4Hz), 1.411(t, 3H, J=6.8Hz), 1.366(s, 6H) | |
13C-NMR (CDCl 3) : 193.599, 164.605, 160.395, 158.879, 154.891, 154.317, 135.459, 133.157, 128.641, 128.364, 127.786, 127.088, 117.880, 117.249, 114.782, 107.335, 106.616, 99.520, 95.947, 81.138, 76.028, 70.810, 63.914, 55.636, 54.542, 27.569, 14.561 | ||
실시예 4 | 1H-NMR (CDCl 3) : 8.074(d, 1H, J=8.8Hz), 7.32~7.39(m, 5H), 7.010(d, 1H, J=8.0Hz), 6.599(dd, 1H, J=8.8, 2.0Hz), 6.533(d, 1H, J=8.0Hz), 6.506(d, 1H, J=2.0Hz), 6.384(d, 1H, J=10.0Hz), 5.467(d, 1H, J=10.0Hz), 5.132(s, 2H), 5.097(s, 2H), 4.523(d, 2H, J=6.4Hz), 3.844(s, 3H), 3.520(t, 1H, J=6.4Hz), 1.368(s, 6H) | |
13C-NMR (CDCl 3) : 194.139, 165.340, 160.469, 154.230, 153.719, 135.322, 133.295, 130.284, 129.700, 128.760, 128.571, 127.896, 126.099, 117.908, 117.245, 114.330, 112.064, 106.223, 99.169, 80.718, 75.488, 70.941, 61.432, 55.627, 27.528 | ||
실시예 5 | 1H-NMR (CDCl 3) : 8.060(d, 1H, J=8.8Hz), 7.355~7.340(m, 5H), 7.006(d, 1H, J=8Hz), 6.587(dd, 1H, J=8.8, 1.6Hz), 6.539(s, 1H), 6.514(s, 1H), 6.376(d, 1H, J=9.6Hz), 5.458(d, 1H, J=10Hz), 5.125(s, 2H), 5.091(s, 2H), 4.519(s, 2H), 3.961(t, 2H, J=6.8), 3.599(br, 1H), 1.855~1.7768(m, 2H), 1.364(s, 6H), 1.036(t, 3H, J=7.2Hz) | |
13C-NMR (CDCl 3) : 194.102, 164.977, 160.511, 154.234, 153.697, 135.367, 133.230, 130.249, 129.676, 128.736, 128.539, 127.905, 126.110, 117.653, 117.245, 114.316, 112.032, 106.766, 99.466, 80.709, 75.467, 70.922, 69.902, 61.415, 27.518, 22.342, 10.388 | ||
실시예 6 | 1H-NMR (CDCl 3) : 8.057(d, 1H, J=8.8Hz), 7.378~7.324(m, 5H), 7.008(d, 1H, J=8Hz), 6.575(dd, 1H, J=8.8, 2Hz), 6.530(d, 1H, J=8Hz), 6.484(d, 1H, J=2.4Hz), 6.380(d, 1H, J=10Hz), 5.461(d, 1H, J=9.6Hz), 5.128(s, 2H), 5.096(s, 2H), 4.645~4.585(m, 1H), 4.522(d, 2H, J=4Hz), 3.555(br, 1H), 1.366(s, 6H), 1.350(s, 3H), 1.335(s, 3H) | |
13C-NMR (CDCl 3) : 194.066, 163.881, 160.601, 154.263, 153.714, 135.417, 133.222, 130.254, 129.692, 128.751, 128.532, 127.869, 126.117, 117.443, 117.263, 114.327, 112.039, 107.420, 100.503, 80.709, 75.476, 70.903, 70.408, 61.439, 27.526, 21.860 | ||
실시예 7 | 1H-NMR (CDCl 3) : 8.061(d, 1H, J=8.8Hz), 7.356~7.342(m, 5H), 7.006(d, 1H, J=8.4Hz), 6.571(dd, 1H, J=8.8, 1.6Hz), 6.558(d, 1H, J=14.4Hz), 6.513(d, 1H, J=4.4Hz), 6.375(d, 1H, J=10Hz), 5.458(d, 1H, J=10Hz), 5.125(s, 2H), 5.092(s, 2H), 4.519(d, 2H, J=6.4Hz), 4.004(t, 2H, J=11.2Hz), 3.537(t, 1H, J=6.4Hz), 1.803~1.749(m, 2H), 1.532~1.409(m, 2H), 1.365(s, 6H), 0.977(t, 3H, J=7.2Hz) | |
13C-NMR (CDCl 3) : 194.120, 164.999, 160.515, 154.259, 153.713, 135.375, 133.257, 130.258, 129.697, 128.751, 128.558, 127.923, 126.113, 117.645, 114.325, 112.044, 106.759, 99.471, 80.722, 75.478, 70.928, 68.142, 61.453, 31.020, 27.528, 19.109, 13.759 | ||
실시예 8 | 1H-NMR (CDCl 3) : 8.059(d, 1H, J=8.8Hz), 7.355~7.324(m, 5H), 7.006(d, 1H, J=8Hz), 6.589(dd, 1H, J=8, 2Hz), 6.529(d, 1H, J=8Hz), 6.505(d, 1H, J=2Hz), 6.375(d, 1H, J=10Hz), 5.458(d, 1H, J=10Hz), 5.125(s, 2H), 5.091(s, 2H), 4.519(s, 2H), 3.995(t, 2H, J=6.4Hz), 3.544(br, 1H), 1.805~1.752(m, 2H), 1.455~1.388(m, 4H), 1.365(s, 6H), 0.935(t, 3H, J=6.8Hz) | |
13C-NMR (CDCl 3) : 194.117, 164.992, 160.515, 154.262, 153.715, 135.379, 133.258, 130.260, 129.697, 128.752, 128.557, 127.923, 126.117, 117.651, 117.651, 114.329, 112.047, 106.760, 99.474, 80.725, 75.479, 70.931, 68.448, 61.453, 28.694, 28.109, 27.532, 22.363, 13.961 | ||
실시예 9 | 1H-NMR (CDCl 3) : 8.061(d, 1H, J=8.8Hz), 7.382~7.325(m, 5H), 7.007(d, 1H, J=8Hz), 6.588(dd, 1H, J=8.8, 2.4Hz), 6.530(d, 1H, J=8.4Hz), 6.506(d, 1H, J=2Hz), 6.377(d, 1H, J=10Hz), 5.459(d, 1H, J=9.6Hz), 5.126(s, 2H), 5.093(s, 2H), 4.519(d, 2H, J=6.8Hz), 3.996(t, 2H, J=6.4Hz), 3.527(t, 1H, J=6.8Hz), 1.798~1.744(m, 2H), 1.465~1.316(m, 6H), 1.366(s, 6H), 0.910(t, 3H, J=5.6Hz) | |
13C-NMR (CDCl 3) : 194.114, 164.998, 160.517, 154.252, 153.714, 135.382, 133.249, 130.257, 129.695, 128.747, 128.551, 127.917, 126.115, 117.656, 117.258, 114.327, 112.046, 106.773, 99.479, 80.720, 75.478, 70.934, 68.463, 61.438, 31.460, 28.959, 27.530, 25.569, 22.527, 13.983 | ||
실시예 10 | 1H-NMR (CDCl 3) : 8.063(d, 1H, J=8.8Hz), 7.364~7.319(m, 5H), 7.005(d, 1H, J=8.4Hz), 6.607(dd, 1H, J=8.8, 2Hz), 6.577(d, 1H, J=2Hz), 6.529(d, 1H, J=8.4Hz), 6.379(d, 1H, J=10Hz), 5.463(d, 1H, J=10Hz), 5.125(s, 2H), 5.081(s, 2H), 4.516(s, 2H), 4.162(d, 2H, J=5.2, 3.2Hz), 3.748(d, 2H, J=5.2, 3.2Hz), 3.445(br, 1H), 3.435(s, 3H), 1.364(s, 6H) | |
13C-NMR (CDCl 3) : 194.140, 164.523, 160.419, 154.227, 153.735, 135.332, 133.278, 130.305, 129.702, 128.762, 128.569, 127.883, 126.104, 118.112, 117.241, 114.353, 112.089, 106.535, 99.968, 80.731, 75.504, 70.966, 70.662, 67.612, 61.447, 59.236, 27.546 | ||
실시예 11 | 1H-NMR (CDCl 3) : 8.074(d, 1H, J=8.8Hz), 7.411~7.340(m, 10H), 7.011(d, 1H, J=8Hz), 6.682(dd, 1H, J=8.8, 2Hz), 6.592(d, 1H, J=2Hz), 6.536(d, 1H, J=8Hz), 6.384(d, 1H, J=10Hz), 5.468(d, 1H, J=10Hz), 5.130(s, 2H), 5.106(s, 2H), 5.073(s, 2H), 4.522(d, 2H, J=5.2Hz), 3.444(br, 1H), 1.370(s, 6H) | |
13C-NMR (CDCl 3) : 194.140, 164.450, 160.458, 154.252, 153.753, 135.848, 135.315, 133.317, 130.312, 129.727, 128.782, 128.738, 128.594, 128.373, 127.903, 127.519, 126.110, 118.138, 117.261, 114.358, 112.102, 107.104, 100.031, 80.742, 75.512, 70.981, 70.381, 61.477, 27.556 | ||
실시예 12 | 1H-NMR (CDCl 3) : 8.051(d, 1H, J=8.8Hz), 7.439~7.350(m, 5H), 7.055(d, 1H, J=8.4Hz), 6.664(dd, 1H, J=8.8, 2.4Hz), 6.614(d, 1H, J=10Hz), 6.572(d, 1H, J=10Hz), 6.515(d, 1H, J=2Hz), 5.655(d, 1H, J=9.6Hz), 5.161(s, 2H), 5.120(s, 2H), 4.168(d, 2H, J=2.8Hz), 3.830(s, 3H), 3.610(br, 1H), 1.426(s, 6H) | |
13C-NMR (CDCl 3) : 194.073, 164.558, 161.291, 154.335, 153.806, 135.859, 133.217, 130.426, 129.721, 128.712, 128.578, 127.523, 126.169, 117.842, 117.449, 114.622, 112.180, 106.662, 98.960, 80.4778, 75.628, 70.351, 61.520, 55.518, 27.555 | ||
실시예 13 | 1H-NMR (CDCl 3) : 8.055(d, 1H, J=8.8Hz), 7.425~7.345(m, 5H), 7.037(d, 1H, J=8.4Hz), 6.646(dd, 1H, J=8.8, 2Hz), 6.610(d, 1H, J=10Hz), 6.556(d, 1H, J=8Hz), 6.479(d, 1H, J=2Hz), 5.655(d, 1H, J=10Hz), 5.229(s, 2H), 5.105(s, 2H), 4.643(s, 2H), 4.127(br, 1H), 4.058(q, 2H, J=14Hz), 1.434(t, 3H, J=5.6Hz), 1.417(s, 6H) | |
13C-NMR (CDCl 3) : 194.514, 164.547, 160.795, 154.849, 153.833, 135.869, 133.204, 130.221, 129.790, 128.700, 128.328, 127.499, 126.189, 117.822, 114.303, 111.932, 106.680, 99.441, 80.741, 75.368, 70.308, 64.232, 61.752, 27.379, 14.710 | ||
실시예 14 | 1H-NMR (CDCl 3) : 8.063(d, 1H, J=8.8Hz), 7.412~7.362(m, 5H), 7.039(d, 1H, J=8.4Hz), 6.648(dd, 1H, J=8.8, 2Hz), 6.593(d, 1H, J=10Hz), 6.558(d, 1H, J=8.4Hz), 6.493(d, 1H, J=2.4Hz), 5.646(d, 1H, J=9.6Hz), 5.219(s, 2H), 5.109(s, 2H), 4.631(s, 2H), 4.2(br, 1H), 3.955(t, 2H, J=6.8Hz), 1.832~1.814(m, 2H), 1.426(s, 6H), 1.012(t, 3H, 7.6Hz) | |
13C-NMR (CDCl 3) : 194.386, 164.551, 160.892, 154.701, 153.796, 135.888, 133.258, 130.245, 129.784, 128.699, 128.546, 127.503, 126.244, 117.782, 117.662, 114.387, 112.016, 106.630, 99.476, 80.696, 75.409, 70.322, 61.716, 27.424, 22.400, 10.871 | ||
실시예 15 | 1H-NMR (CDCl 3) : 8.063(d, 1H, J=8.8Hz), 7.433~7.336(m, 5H), 7.043(d, 1H, J=8Hz), 6.648(dd, 1H, J=8.8, 2.4Hz), 6.602(d, 1H, J=10Hz), 6.559(d, 1H, J=8Hz), 6.497(d, 1H, J=2.4Hz), 5.648(d, 1H, J=9.6Hz), 5.208(s, 2H), 5.110(s, 2H), 4.629(d, 2H, J=3.6Hz), 3.990(m, 3H), 1.815~1.744(m, 2H), 1.486~1.396(m, 8H), 0.928(t, 3H, 7.2Hz) | |
13C-NMR (CDCl 3) : 194.341, 164.543, 160.890, 154.634, 153.788, 135.888, 133.253, 130.303, 129.791, 128.699, 128.327, 127.509, 126.250, 117.781, 117.605, 114.379, 112.049, 106.595, 99.491, 80.697, 75.443, 70.318, 68.405, 61.678, 30.997, 27.495, 19.337, 13.709 | ||
실시예 16 | 1H-NMR (CDCl 3) : 8.069(d, 1H, J=8.8Hz), 7.426~7.347(m, 5H), 7.062(d, 1H, J=8Hz), 6.688~6.652(m, 2H), 6.558(d, 1H, J=8.4Hz), 6.487(d, 1H, J=2.4Hz), 5.641(d, 1H, J=10Hz), 5.244(s, 2H), 5.110(s, 2H), 4.614(d, 2H, J=6.4Hz), 4.122(t, 2H, J=4.8Hz), 3.693~3.620(m, 3H), 3.228(s, 3H), 1.420(s, 6H) | |
13C-NMR (CDCl 3) : 194.068, 164.393, 160.4485, 154.308, 153.700, 135.851, 133.172, 130.359, 129.823, 128.703, 128.336, 127.495, 126.260, 118.109, 117.483, 114.640, 112.187, 107.077, 99.757, 80.789, 75.629, 70.370, 70.335, 67.570, 61.340, 58.674, 27.617 | ||
실시예 17 | 1H-NMR (CDCl 3) : 7.971(d, 1H, J=8Hz), 7.433~7.339(m, 5H), 7.011(d, 1H, J=8.4Hz), 6.924(d, 1H, J=8Hz), 6.865(s, 1H), 6.538(d, 1H, J=8.4Hz), 6.389(d, 1H, J=10Hz), 5.475(d, 1H, J=10Hz), 5.138(d, 2H, J=8Hz), 4.515(s, 2H), 3.310(br, 1H), 2.707~2.619(m, 2H), 1.369(s, 6H), 1.245(t, 3H, J=7.6Hz) | |
13C-NMR (CDCl 3) : 195.369, 158.868, 153.761, 152.515, 135.625, 131.324, 130.363, 129.697, 128.738, 128.509, 127.499, 126.083, 122.421, 121.132, 117.210, 114.408, 112.166, 112.135, 80.841, 75.540, 70.913, 61.402, 29.204, 27.859, 15.014 | ||
실시예 18 | 1H-NMR (CDCl 3) : 8.168(d, 2H, J=8.8Hz), 7.950(d, 1H, J=8Hz), 7.545(d, 2H, J=8.8Hz), 7.020(d, 1H, J=8.0Hz), 6.959(dd, 1H, J=8, 1.2Hz), 6.795(s, 1H), 6.552(d, 1H, J=8Hz), 6.428(d, 1H, J=9.6Hz), 5.509(d, 1H, J=10Hz), 5.233(s, 2H), 5.131(s, 2H), 4.532(d, 2H, J=6.4Hz), 3.134(t, 1H, J=6.4Hz), 2.671(q, 2H, J=15.2Hz), 1.344(s, 6H), 1.232(t, 3H, J=7.6Hz) | |
13C-NMR (CDCl 3) : 194.892, 158.011, 153.937, 152.558, 147.782, 142.812, 131.4406, 130.706, 129.797, 128.125, 127.519, 125.970, 123.970, 123.883, 122.518, 121.668, 116.946, 114.550, 113.201, 112.537, 112.045, 80.751, 75.627, 69.546, 61.309, 29.170, 27.497, 15.017 | ||
실시예 19 | 1H-NMR (CDCl 3) : 7.948(d, 1H, J=8Hz), 7.065(d, 1H, J=8Hz), 6.992(d, 1H, J=8Hz), 6.758(s, 1H), 6.618(d, 1H, J=10Hz), 6.580(d, 1H, J=8Hz), 5.660(d, 1H, J=10Hz), 5.194(s, 2H), 4.630(d, 2H, J=6Hz), 3.875(s, 3H), 3.431(t, 1H, J=6.4Hz), 2.624(t, 2H, J=7.6Hz), 1.692~1.617(m, 2H), 1.431(s, 6H), 0.955(t, 3H, J=7.2Hz) | |
13C-NMR (CDCl 3) : 195.352, 159.530, 154.279, 153.804, 151.120, 131.081, 130.458, 129.702, 126.156, 121.981, 121.410, 117.421, 114.635, 112.208, 111.466, 80.598, 75.635, 61.525, 55.410, 38.210, 27.544, 24.110, 13.755 | ||
실시예 20 | 1H-NMR (CDCl 3) : 7.967(d, 1H, J=8Hz), 7.430~7.320(m, 5H), 7.010(d, 1H, J=8Hz), 6.998(d, 1H, J=8Hz), 6.845(s, 1H), 6.538(d, 1H, J=8Hz), 6.387(d, 1H, J=10Hz), 5.473(d, 1H, J=10Hz), 5.163(s, 2H), 5.153(s, 2H), 4.514(s, 2H), 3.389(s, 1H), 2.611(t, 2H, J=7.6Hz), 1.674~1.600(m, 2H), 1.368(s, 6H), 0.934(t, 3H, J=7.2Hz) | |
13C-NMR (CDCl 3) : 195.343, 158.738, 155.662, 154.090, 153.688, 151.024, 136.179, 131.156, 130.323, 129.651, 128.691, 128.463, 127.890, 126.045, 122.282, 121.682, 117.167, 114.350, 113.694, 112.657, 112.104, 80.826, 75.495, 70.824, 61.355 | ||
실시예 21 | 1H-NMR (CDCl 3) : 7.967(d, 1H, J=8Hz), 7.306(s, 4H), 7.025(d, 1H, J=8Hz), 6.919(dd, 1H, J=8, 1.2Hz), 6.811(s, 1H), 6.558(d, 1H, J=8.4Hz), 6.370(d, 1H, J=10Hz), 5.493(d, 1H, J=10Hz), 5.112(s, 2H), 5.082(s, 2H), 4.524(s, 2H), 3.296(br, 1H), 2.616(t, 2H, J=7.6Hz), 1.697~1.604(m, 4H), 1.377(s, 6H), 0.940(t, 3H, J=7.6Hz) | |
- | ||
실시예 22 | 1H-NMR (CDCl 3) : 7.961(d, 1H, J=8Hz), 7.401(d, 1H, J=2Hz), 7.366(d, 1H, J=8Hz), 7.227(d, 1H, 2.4Hz), 7.206(d, 1H, J=2Hz), 7.026(d, 1H, 8.4Hz), 6.933(dd, 1H, J=8, 0.8Hz), 6.804(s, 1H), 6.556(d, 1H, J=8.4Hz), 6.398(d, 1H, J=9.6Hz), 5.504(d, 1H, J=10Hz), 5.172(s, 2H), 5.123(s, 2H), 4.540(s, 2H), 3.3(br, 1H), 2.623(t, 2H, J=7.6Hz), 1.684~1.610(m, 4H), 1.382(s, 6H), 0.944(t, 3H, J=7.2Hz) | |
- | ||
실시예 23 | 1H-NMR (CDCl 3) : 7.961(d, 1H, J=8Hz), 7.245(d, 2H, J=8.8Hz), 7.113(d, 2H, J=8Hz), 7.007(d, 1H, 8.4Hz), 6.889(dd, 1H, J=8, 1.2Hz), 6.842(d, 1H, J=1.2Hz), 6.539(dd, 1H, J=8.4, 0.4Hz), 6.392(dd, 1H, J=10, 0.8Hz), 5.466(d, 1H, J=9.6Hz), 5.124(s, 2H), 5.067(s, 2H), 4.504(s, 2H), 3.3(br, 1H), 2.611(t, 2H, J=7.6Hz), 2.347(s, 2H), 1.679~1.622(m, 2H), 1.369(s, 6H), 0.938(t, 3H, J=7.2Hz) | |
13C-NMR (CDCl 3) : 195.3316, 158.874, 154.093, 153.705, 151.006, 138.261, 132.530, 131.130, 130.271, 129.607, 129.336, 128.062, 126.084, 122.313, 121.608, 117.247, 114.379, 112.676, 112.071, 80.901, 75.477, 70.780, 61.354, 38.248, 27.491, 24.037, 21.170, 13.703 | ||
실시예 24 | 1H-NMR (CDCl 3) : 8.154(d, 2H, J=8.4Hz), 7.936(d, 1H, J=8Hz), 7.538(d, 2H, J=8.8Hz), 7.112(d, 1H, 8Hz), 6.930(d, 1H, J=8Hz), 6.773(s, 1H), 6.543(d, 1H, J=8Hz), 6.423(d, 1H, J=10Hz), 5.499(d, 1H, J=6Hz), 5.225(s, 2H), 5.129(s, 2H), 4.504(s, 2H), 3.240(br, 1H), 2.600(t, 2H, J=7.6Hz), 1.655~1.588(m, 2H), 1.337(s, 6H), 0.917(t, 3H, J=7.2Hz) | |
13C-NMR (CDCl 3) : 194.877, 157.904, 153.873, 153.719, 151.043, 147.723, 142.811, 131.228, 130.668, 129.761, 128.101, 125.952, 123.847, 122.482, 112.220, 121.974, 116.910, 114.515, 112.614, 112.494, 80.738, 75.536, 69.504, 61.207, 38.178, 27.461, 24.006, 13.641 | ||
실시예 25 | 1H-NMR (CDCl 3) : 8.130(dd, 1H, J=8, 1.2Hz), 7.907(d, 1H, J=8Hz), 7.712(d, 1H, J=7.6Hz), 7.594(td, 1H, 7.6, 1.2Hz), 7.497(dd, 1H, J=8.4, 1.6Hz), 7.040(d, 1H, J=8Hz), 6.927(dd, 1H, J=8, 1.2Hz), 6.747(s, 1H), 6.555(d, 1H, J=8.4Hz), 6.485(d, 1H, J=9.6Hz), 5.561(s, 2H), 5.535(d, 1H, J=10Hz), 5.183(s, 2H), 4.576(d, 2H, J=5.6Hz), 3.205(br, 1H), 2.573(t, 2H, J=4Hz), 1.636~1.579(m, 2H), 1.359(s, 6H), 0.906(t, 3H, J=7.6Hz) | |
13C-NMR (CDCl 3) : 195.109, 157.878, 153.977, 153.791, 151.084, 147.120, 134.110, 132.256, 131.117, 130.597, 129.793, 129.029, 128.971, 126.048, 125.171, 122.525, 122.189, 117.065, 114.542, 112.975, 112.387, 80.358, 75.657, 67.659, 38.190, 27.557, 24.064, 13.653 | ||
실시예 26 | 1H-NMR (CDCl 3) : 7.980(d, 1H, J=8.4Hz), 7.388~7.322(m, 5H), 7.012(d, 1H, J=8.4Hz), 6.950(dd, 1H, J=8, 1.2Hz), 6.889(s, 1H), 6.540(d, 1H, J=8Hz), 6.393(d, 1H, J=9.6Hz), 5.478(d, 1H, J=10Hz), 5.155(s, 2H), 5.138(s, 2H), 4.519(d, 2H, J=4.8Hz), 3.381(br, 1H), 2.928(m, 1H), 1.400(s, 6H), 1.261~1.215(m, 6H) | |
13C-NMR (CDCl 3) : 195.327, 257.109, 154.077, 153.683, 131.276, 130.306, 129.642, 128.679, 128.457, 127.922, 126.031, 122.391, 119.581, 117.161, 114.329, 112.088, 80.805, 75.483, 61.319, 34.480, 27.502 | ||
실시예 27 | 1H-NMR (CDCl 3) : 7.961(d, 1H, J=8Hz), 7.359~7.279(m, 5H), 7.011(d, 1H, J=8Hz), 6.901(d, 1H, J=8Hz), 6.842(s, 1H), 6.539(d, 1H, J=8Hz), 6.395(d, 1H, J=9.6Hz), 5.476(d, 1H, J=9.6Hz), 5.150(s, 2H), 5.126(s, 2H), 4.516(d, 2H, J=4.8Hz), 3.302(br, 1H), 2.634(t, 2H, J=7.6Hz), 1.587(m, 2H), 1.417~1.331(m, 2H), 1.370(s, 6H), 0.923(t, 3H, J=7.2Hz) | |
13C-NMR (CDCl 3) : 195.358, 158.764, 154.118, 153.717, 151.297, 135.582, 131.196, 130.340, 129.680, 128.711, 128.348, 127.909, 126.058, 122.263, 121.664, 117.189, 114.372, 112.629, 112.127, 80.842, 75.518, 70.840, 61.386, 35.941, 33.033, 27.534, 22.420, 13.857 | ||
실시예 28 | 1H-NMR (CDCl 3) : 7.968(d, 1H, J=8Hz), 7.369~7.208(m, 5H), 7.011(d, 1H, J=8.4Hz), 6.905(d, 1H, J=8Hz), 6.840(s, 1H), 6.539(d, 1H, J=8Hz), 6.356(d, 1H, J=10Hz), 5.474(d, 1H, J=9.6Hz), 5.153(s, 2H), 5.127(s, 2H), 4.516(d, 2H, J=6.4Hz), 3.298(t, 1H, J=6.8Hz), 2.625(t, 2H, J=7.6Hz), 1.626~1.592(m, 2H), 1.417~1.216(m, 10H), 0.887(t, 3H, J=6.4Hz) | |
- | ||
실시예 29 | 1H-NMR (CDCl 3) : 7.972(d, 1H, J=7.6Hz), 7.405~7.322(m, 5H), 7.012(d, 1H, J=8Hz), 6.941(d, 1H, J=8.4Hz), 6.925(s, 1H), 6.540(d, 1H, J=8.4Hz), 6.387(d, 1H, J=10Hz), 5.479(d, 1H, J=10Hz), 5.169(s, 2H), 5.146(s, 2H), 4.511(d, 2H, J=5.6Hz), 3.608(t, 2H, J=6.4Hz), 3.332(s, 3H), 3.272(br, 1H), 2.899(t, 2H, J=6.4Hz), 1.416(s, 6H) | |
13C-NMR (CDCl 3) : 195.380, 158.685, 154.084, 153.726, 147.462, 135.527, 131.269, 130.372, 129.687, 128.723, 128.506, 127.928, 126.041, 122.783, 121.901, 117.169, 114.367, 113.245, 112.154, 80.841, 75.527, 70.873, 61.375, 58.741, 36.433, 27.537 | ||
실시예 30 | 1H-NMR (CDCl 3) : 7.526(d, 1H, J=8Hz), 7.496~7.291(m, 5H), 7.270(d, 1H, J=8Hz), 7.016(d, 1H, J=8.4Hz), 6.546(d, 1H, 8Hz), 6.432(d, 1H, J=8Hz), 5.498(d, 1H, J=10Hz), 5.135(s, 2H), 4.820(s, 2H), 4.539(s, 2H), 3.201(br, 1H), 2.332(s, 3H), 2.236(s, 3H), 1.361(s, 6H) | |
- | ||
실시예 31 | 1H-NMR (CDCl 3) : 7.804(s, 1H), 7.346~7.334(m, 5H), 7.010(d, 1H, J=8.4Hz), 6.826(s, 1H), 6.536(d, 1H, J=8Hz), 6.398(d, 1H, J=10Hz), 5.472(d, 1H, J=10Hz), 5.147(s, 2H), 5.096(s, 2H), 4.517(d, 2H, J=3.6Hz), 3.327(br, 1H), 2.293(s, 3H), 2.233(s, 3H), 1.367(s, 6H) | |
13C-NMR (CDCl 3) : 195.485, 156.948, 154.1449, 153.705, 144.902, 135.781, 131.672, 130.322, 129.657, 128.695, 128.409, 127.827, 126.078, 121.959, 117.197, 114.379, 114.009, 112.105, 80.880, 75.510, 70.948, 61.410, 27.529, 20.534, 18.974 | ||
실시예 32 | 1H-NMR (CDCl 3) : 8.119(d, 1H, J=8Hz), 7.536~7.205(m, 12H), 7.031(d, 1H, J=8.4Hz), 6.560(d, 1H, J=8Hz), 6.423(d, 1H, J=9.6Hz), 5.504(d, 1H, J=9.6Hz), 5.213(s, 4H), 4.541(d, 2H, J=5.6Hz), 3.240(t, 1H, J=6.4Hz), 1.385(s, 6H) | |
13C-NMR (CDCl 3) : 195.363, 158.944, 154.081, 153.770, 148.050, 139.675, 135.426, 131.754, 130.445, 129.738, 128.969, 128.799, 128.615, 128.550, 127.963, 127.229, 126.046, 120.287, 117.167, 114.418, 112.231, 111.393, 80.924, 75.570, 71.064, 61.410, 27.570 | ||
실시예 33 | 1H-NMR (CDCl 3) : 8.037(d, 1H, J=8.4Hz), 7.419~7.009(m, 11H), 6.603~6.535(m, 3H), 6.411(d, 1H, J=10Hz), 5.491(d, 1H, J=9.6Hz), 5.157(s, 2H), 5.035(s, 2H), 4.532(d, 2H, J=6.8Hz), 3.400(t, 1H, J=6.4Hz), 1.378(s, 6H) | |
13C-NMR (CDCl 3) : 194.214, 163.765, 160.375, 154.848, 154.168, 153.739, 135.098, 133.150, 130.344, 130.076, 129.724, 128.761, 128.577, 127.904, 126.0660, 124.910, 120.330, 119.189, 119.135, 144.344, 112.135, 110.042, 101.837, 80.752, 75.510, 70.976, 61.407, 27.536 | ||
실시예 34 | 1H-NMR (CDCl 3) : 7.722(d, 1H, J=8.8Hz), 7.486~7.320(m, 10H), 7.013(d, 1H, J=8.4Hz), 6.828(d, 1H, J=8.8Hz), 6.544(d, 1H, J=8.4Hz), 6.418(d, 1H, J=10Hz), 5.481(d, 1H, J=10Hz), 5.162(s, 2H), 5.142(s, 2H), 4.850(s, 2H), 3.406(t, 1H, J=6.4Hz), 2.257(s, 3H), 1.363(s, 6H) | |
13C-NMR (CDCl 3) : 196.210, 161.985, 157.971, 154.160, 153.769, 136.275, 135.967, 130.506, 129.731, 129.099, 128.678, 128.646, 128.461, 128.137, 127.892, 127.126, 126.068, 123.289, 120.738, 117.149, 114.469, 112.222, 107.937, 79.434, 75.569, 61.487, 27.538, 9.705 | ||
실시예 35 | 1H-NMR (CDCl 3) : 8.101(dd, 1H, J=8.8, 6.8Hz), 7.420~7.347(m, 5H), 7.036(d, 1H, J=8Hz), 6.827~6.749(m, 2H), 6.567(d, 1H, J=8Hz), 6.415(d, 2H, J=10Hz), 5.512(d, 1H, J=10Hz), 5.154(s, 2H), 5.123(s, 2H), 4.533(s, 2H), 3.2(br, 1H), 1.393(s, 6H) | |
13C-NMR (CDCl 3) : 194, 168.163, 165.619, 160.334, 160.229, 153.975, 153.772, 134.734, 133.584, 133.472, 130.501, 129.760, 128.858, 128.790, 127.915, 125.969, 121.147, 121.119, 117.070, 114.388, 112.291, 108.852, 108.637, 100.820, 100.560, 80.765, 75.579, 71.388, 27.562 | ||
실시예 36 | 1H-NMR (CDCl 3) : 7.984(d, 1H, J=8Hz), 7.371~7.320(m, 5H), 7.085~6.988(m, 3H), 6.549(d, 1H, J=8Hz), 6.380(d, 1H, J=10Hz), 5.491(d, 1H, J=9.6Hz), 5.119(s, 2H), 5.111(s, 2H), 4.501(s, 2H), 3.002(br, 1H), 1.371(s, 6H) | |
13C-NMR (CDCl 3) : 194, 159, 154.051, 153.893, 140.950, 134.766, 132.341, 130.545, 129.762, 128.855, 128.804, 127.919, 127.397, 125.938, 117.021, 114.402, 113.359, 112.341, 80.803, 75.600, 71.419, 61.322, 27.645 | ||
실시예 37 | 1H-NMR (CDCl 3) : 7.707(d, 1H, J=8Hz), 7.649~7.628(m, 2H), 7.314~7.187(m, 3H), 7.078(d, 1H, J=8Hz), 7.013(s, 1H), 6.601(d, 1H, J=8.4Hz), 6.544(d, 1H, J=10Hz), 5.668(d, 1H, J=10Hz), 5.065(s, 2H), 4.587(s, 2H), 3(br, 1H), 2.676~2.619(m, 2H), 2.433(s, 3H), 1.429(s, 6H), 1.179(t, 3H, J=6.4Hz) | |
13C-NMR (CDCl 3) : 194.769, 153.894, 153.594, 151.474, 147.506, 146.216, 131.482, 130.893, 130.512, 130.008, 129.892, 129.787, 128.425, 127.586, 127.036, 125.931, 122.448, 116.989, 114.608, 112.670, 79.074, 75.811, 28.594, 27.597, 21.739, 14.723 | ||
실시예 38 | 1H-NMR (CDCl 3) : 7.698(d, 1H, J=8Hz), 7.630(d, 2H, J=6.4Hz), 7.248(d, 2H, J=8Hz), 7.176(dd, 1H, J=8, 1.6Hz), 7.078(d, 1H, J=8.4Hz), 6.997(d, 1H, J=1.2Hz), 6.601(d, 1H, J=8.4Hz), 6.548(d, 1H, J=9.6Hz), 5.670(d, 1H, J=10Hz), 5.067(s, 2H), 4.589(d, 2H, J=6.4Hz), 2.949(t, 1H, J=6.4Hz), 2.581(t, 2H, J=7.6Hz), 2.431(s, 3H), 1.605~1.549(m, 2H), 1.430(s, 6H), 0.899(t, 3H, J=7.2Hz) | |
- | ||
실시예 39 | 1H-NMR (CDCl 3) : 7.814(d, 1H, J=8.8Hz), 7.659(dd, 2H, J=6.8, 1.6Hz), 7.239(d, 2H, J=8Hz), 7.069(d, 1H, J=8Hz), 6.858(dd, 1H, J=8.8, 1.6Hz), 6.786(s, 1H), 6.598(d, 1H, J=8Hz), 6.544(dd, 1H, J=9.6, 0.4Hz), 5.667(d, 1H, J=10Hz), 5.013(s, 2H), 4.561(d, 2H, J=5.6Hz), 4.032(q, 2H, J=14, 7.2Hz), 3.05(br, 1H), 2.423(s, 3H), 1.431(s, 6H), 1.400(t, 3H, J=4.8Hz) | |
13C-NMR (CDCl 3) : 193.271, 163.431, 153.875, 153.718, 149.422, 146.293, 132.214, 131.584, 130.851, 130.063, 129.825, 128.329, 125.979, 121.846, 117.039, 114.607, 113.663, 112.501, 108.537, 79.121, 75.860, 64.363, 61.228, 27.604, 21.743, 14.429 | ||
실시예 40 | 1H-NMR (CDCl 3) : 7.814(d, 1H, J=8.8Hz), 7.662(dd, 2H, J=6.8, 1.6Hz), 7.241(d, 2H, J=8Hz), 7.070(d, 1H, J=8.4Hz), 6.864(dd, 1H, J=8.8, 1.6Hz), 6.769(d, 1H, J=2.4Hz), 6.598(dd, 1H, J=8, 0.4Hz), 6.533(dd, 1H, J=10, 0.4Hz), 5.668(d, 1H, J=10Hz), 5.017(s, 2H), 4.563(d, 2H, J=4.4Hz), 3.905(t, 2H, J=6.8Hz), 3.079(br, 1H), 2.423(s, 3H), 1.829~1.777(m, 2H), 1.431(s, 6H), 1.027(t, 3H, J=3.6Hz) | |
13C-NMR (CDCl 3) : 193.262, 163.614, 153.859, 149.399, 146.284, 132.196, 131.800, 131.555, 130.840, 129.943, 129.814, 128.349, 125.969, 121.798, 117.035, 114.596, 113.707, 112.484, 108.528, 79.114, 75.790, 70.229, 27.719, 22.198, 21.734, 10.329 | ||
실시예 41 | 1H-NMR (CDCl 3) : 7.942(d, 1H, J=9.2Hz), 7.043(d, 1H, J=8Hz), 6.975(s, 2H), 6.852(dd, 1H, J=8.8, 2.4Hz), 6.575(d, 1H, J=7.6Hz), 6.544(s, 1H), 6.258(d, 1H, J=2.4Hz), 5.648(d, 1H, J=10Hz), 5.074(s, 2H), 4.562(s, 2H), 3.731(t, 2H, J=6.4Hz), 3.1(br, 1H), 2.517(s, 6H), 2.321(s, 3H), 1.750~1.698(m, 2H), 1.422(s, 6H), 0.970(t, 3H, J=7.6Hz) | |
13C-NMR (CDCl 3) : 193.390, 163.533, 153.843, 153.775, 149.753, 144.601, 140.337, 132.494, 131.984, 130.764, 130.708, 129.709, 125.983, 122.210, 117.178, 114.649, 113.666, 112.400, 107.455, 79.339, 75.760, 70.058, 61.285, 27.558, 22.682, 22.116, 21.142, 10.241 | ||
실시예 42 | 1H-NMR (CDCl 3) : 8.051(d, 1H, J=8.8Hz), 7.042(d, 1H, J=8.4Hz), 6.618~6.548(m, 3H), 6.415(d, 1H, J=2Hz), 6.045~6.029(m, 1H), 5.652(d, 1H, J=9.6Hz), 5.392(dd, 1H, J=17.2, 1.2Hz), 5.296(dd, 1H, J=11.2, 0.8Hz), 5.220(s, 2H), 4.634(d, 2H, J=6.8Hz), 4.584(d, 2H, J=5.6Hz), 4.009~3.953(m, 3H), 1.849~1.797(m, 2H), 1.431(s, 6H), 1.044(t, 3H, J=7.6Hz) | |
13C-NMR (CDCl 3) : 194.362, 165.011, 160.388, 154.687, 153.791, 133.236, 132.016, 130.230, 129.753, 126.206, 119.138, 117.748, 117.546, 114.381, 111.969, 106.68, 99.310, 880.667, 75.423, 69.890, 69.627, 61.722, 27.448, 22.366, 10.406 | ||
실시예 43 | 1H-NMR (CDCl 3) : 7.045(d, 1H, J=8.4Hz), 6.996(s, 2H), 6.728(d, 1H, J=2Hz), 6.578(s, 1H), 6.555(d, 1H, J=2Hz), 6.521(dd, 1H, J=8.8, 2Hz), 5.989~5.920(m, 1H), 5.649(d, 1H, J=10Hz), 5.377~5.305(m, 2H), 5.194(s, 2H), 4.610(s, 2H), 4.511(d, 2H, J=5.6Hz), 2.571(s, 6H), 2.334(s, 3H), 1.425(s, 6H) | |
13C-NMR (CDCl 3) : 194.5, 159.172, 154.216, 153.891, 144.344, 140.427, 132.524, 131.977, 131.589, 131.305, 130.549, 129.832, 125.997, 123.1110, 119.710, 117.408, 114.5507, 114.441, 112.325, 110.490, 107.381, 80.673, 75.564, 70.050, 61.556, 27.514, 22.745, 21.106 | ||
실시예 44 | 1H-NMR (CDCl 3) : 7.820(d, 1H, J=8.8Hz), 7.660(d, 1H, J=8.4Hz), 7.266~7.233(m, 2H), 7.071(d, 1H, J=8Hz), 6.888(dd, 1H, J=8.8, 2.4Hz), 6.806(d, 1H, J=2.4Hz), 6.600(dd, 1H, J=8.4, 0.4Hz), 6.532(dd, 1H, J=9.6, 0.4Hz), 6.028~5.959(m, 1H), 5.669(d, 1H, J=10Hz), 5.422~5.318(m, 2H), 5.220(s, 2H), 4.567~4.526(m, 4H), 3.05(br, 1H), 2.425(s, 3H), 1.431(s, 6H) | |
13C-NMR (CDCl 3) : 193.285, 162.930, 153.859, 153.679, 149.347, 146.328, 132.220, 131.702, 131.497, 130.862, 130.069, 129.827, 128.336, 125.948, 122.144, 118.717, 117.011, 114.595, 113.897, 112.504, 108.808, 79.126, 75.796, 69.325, 61.209, 27.586, 21.749 | ||
실시예 45 | 1H-NMR (CDCl 3) : 7.942(d, 1H, J=8.8Hz), 7.044(d, 1H, J=8Hz), 6.978(s, 2H), 6.876(dd, 1H, J=8.8, 2Hz), 6.586~6.545(m, 2H), 6.293(d, 1H, J=2.4Hz), 5.938~5.869(m, 1H), 5.647(d, 1H, J=10Hz), 5.327~5.263(m, 2H), 5.156(s, 2H), 4.563(d, 2H, J=2.4Hz), 4.376(d, 2H, J=5.6Hz), 3.092(br, 1H), 2.529(s, 6H), 2.334(s, 3H), 1.421(s, 6H) | |
13C-NMR (CDCl 3) : 193.422, 162.870, 153.852, 153.741, 149.669, 144.634, 140.332, 132.506, 131.890, 131.706, 130.732, 129.724, 125.976, 122.650, 118.556, 117.161, 114.656, 113.799, 112.430, 107.894, 79.336, 75.767, 69.176, 61.267, 29.330, 22.669, 21.150 | ||
실시예 46 | 1H-NMR (CDCl 3) : 7.814(d, 1H, J=8.8Hz), 7.665(dd, 1H, J=8.4, 2Hz), 7.266(s, 1H), 7.240(d, 1H, J=8Hz), 7.068(d, 1H, J=8.4Hz), 6.858(dd, 1H, J=8.8, 2.4Hz), 6.758(d, 1H, J=2Hz), 6.596(dd, 1H, J=8.4, 0.4Hz), 6.533(d, 1H, J=10Hz), 5.665(d, 1H, J=10Hz), 5.016(s, 2H), 4.561(s, 2H), 3.942(t, 2H, J=6.8Hz), 3.095(br, 1H), 2.421(s, 3H), 1.792~1.722(m, 2H), 1.499~1.392(m, 8H), 0.975(t,, 3H, J=7.2Hz) | |
13C-NMR (CDCl 3) : 193.251, 163.619, 153.863, 153.709, 149.408, 146.273, 132.191, 131.595, 130.836, 130.042, 129.810, 128.355, 125.981, 121.812, 117.040, 113.709, 112.487, 108.519, 79.115, 75.788, 68.483, 61.206, 30.829, 27.594, 21.729, 19.098, 13.711 | ||
실시예 47 | 1H-NMR (CDCl 3) : 8.047(d, 1H, J=8.8Hz), 7.3884~7.324(m, 5H), 6.581(dd, 1H, J=8.8, 2Hz), 6.507(s, 1H), 6.502(s, 1H), 6.422(d, 1H, J=8Hz), 5.401(d, 1H, J=10Hz), 5.116(s, 2H), 5.090(s, 2H), 4.615(s, 2H), 3.959(t, 2H, J=6.8Hz), 3.2(br, 1H), 2.325(s, 3H), 1.836~1.784(m, 2H), 1.355(s, 6H), 1.036(t, 3H, J=7.6Hz) | |
13C-NMR (CDCl 3) : 194.185, 164.941, 160.501, 154.568, 153.073, 139.013, 135.410, 133.214, 129.135, 128.709, 128.515, 127.952, 124.437, 117.703, 117.378, 114.027, 111.673, 106.724, 99.451, 81.045, 75.422, 70.892, 69.899, 56.764, 27.548, 22.352, 19.333, 10.396 | ||
실시예 48 | 1H-NMR (CDCl 3) : 8.048(d, 1H, J=8.8Hz), 7.388~7.297(m, 5H), 6.574(dd, 1H, J=8.8, 2.4Hz), 6.490(d, 1H, J=2Hz), 6.363(d, 1H, J=9.6Hz), 6.206(s, 1H), 5.345(d, 1H, J=9.6Hz), 5.118(s, 2H), 5.090(s, 2H), 4.636(d, 2H, J=5.2Hz), 3.948(t, 2H, J=6.4Hz), 3.782(s, 3H), 3.054(br, 1H), 1.811~1.758(m, 2H), 1.365(s, 6H), 1.030(t, 3H, J=7.6Hz) | |
13C-NMR (CDCl 3) : 193.584, 164.806, 160.403, 158.863, 154.891, 154.301, 135.452, 133.104, 128.805, 128.345, 127.798, 127.061, 117.821, 117.232, 114.778, 107.315, 106.702, 81.117, 75.999, 70.82, 69.844, 55.614, 54.511, 27.550, 22.321, 14.122 | ||
실시예 49 | 1H-NMR (CDCl 3) : 7.952(d, 1H, J=8Hz), 7.380~7.314(m, 5H), 6.901(d, 1H, J=8Hz), 6.855(s, 1H), 6.434(s, 1H), 6.334(d, 1H, J=9.6Hz), 5.410(d, 1H, J=10Hz), 5.138(s, 2H), 5.117(s, 2H), 4.605(d, 2H, J=3.2Hz), 3.050(br, 1H), 2.656(q, 2H, J=15.2, 7.6Hz), 2.318(s, 3H), 1.353(s, 6H), 1.234(t, 3H, J=7.6Hz) | |
13C-NMR (CDCl 3) : 195.367, 158.811, 154.415, 153.049, 152.438, 139.003, 135.578, 131.209, 129.179, 128.630, 128.397, 127.907, 124.342, 122.280, 121.000, 120.907, 117.261, 114.061, 112.049, 111.687, 81.134, 75.415, 70.779, 56.687, 29.130, 27.516, 19.278, 14.979 | ||
실시예 50 | 1H-NMR (CDCl 3) : 7.948(d, 1H, J=8Hz), 7.245(d, 2H, J=3.2Hz), 7.113(d, 2H, 7.6Hz), 6.877(d, 1H, J=8.4Hz), 6.835(s, 1H), 6.437(s, 1H), 6.340(d, 1H, J=10Hz), 5.406(d, 1H, J=9.6Hz), 5.119(s, 2H), 5.064(s, 2H), 4.606(s, 2H), 3.0(br, 1H), 2.603(t, 2H, J=7.6Hz), 2.347(s, 3H), 2.324(s, 3H), 1.673~1.586(m, 2H), 1.338(s, 6H), 0.933(t, 3H, J=7.2Hz) | |
13C-NMR (CDCl 3) : 195.369, 158.846, 154.454, 153.083, 150.926, 138.996, 138.227, 132.552, 131.100, 129.287, 129.145, 128.073, 127.683, 124.369, 122.347, 121.558, 117.353, 114.054, 112.648, 81.231, 75.425, 70.715, 56.739, 38.2321, 27.525, 24.023, 21.149, 19.307, 13.696 | ||
실시예 51 | 1H-NMR (CDCl 3) : 7.956(d, 1H, J=8Hz), 7.048(d, 1H, J=8.4Hz), 6.907(dd, 1H, J=8.8, 0.8Hz), 6.765(s, 1H), 6.615~6.554(m, 2H), 6.073~6.004(m, 1H), 5.650(d, 1H, J=10Hz), 5.389(dd, 1H, J=17.2, 1.2Hz), 5.291(dd, 1H, J=2.4, 1.2Hz), 5.244(s, 2H), 4.629~4.615(m, 4H), 3.8(br, 1H), 2.662(t, 2H, J=7.6Hz), 1.426(s, 6H), 1.245(t, 3H, J=7.6Hz) | |
13C-NMR (CDCl 3) : 195.629, 158.718, 154.543, 153.826, 152.559, 132.231, 131.297, 130.317, 129.774, 126.151, 122.200, 121.036, 118.989, 117.658, 114.410, 112.076, 111.980, 80.768, 75.469, 69.552, 61.660, 29.197, 27.470, 15.023 | ||
실시예 52 | 1H-NMR (CDCl 3) : 7.948(d, 1H, J=8Hz), 7.047(d, 1H, J=8.4Hz), 6.884(dd, 1H, J=8, 1.2Hz), 6.745(s, 1H), 6.601(d, 1H, J=10Hz), 6.562(d, 1H, J=8.4Hz), 6.069~6.000(m, 1H), 5.650(d, 1H, J=9.6Hz), 5.408~5.217(m, 2H), 5.244(s, 2H), 4.641~4.606(m, 4H), 3.800(br, 1H), 2.605(t, 2H, J=7.6Hz), 1.677~1.602(m, 2H), 1.429(s, 6H), 0.943(t, 3H, J=5.6Hz) | |
13C-NMR (CDCl 3) : 195.608, 158.610, 154.521, 153.801, 151.042, 132.214, 131.152, 130.305, 129.747, 126.158, 122.208, 121.623, 118.961, 117.643, 114.406, 112.557, 112.062, 80.760, 75.455, 69.533, 61.637, 38.252, 27.459, 24.051, 13.713 | ||
실시예 53 | 1H-NMR (CDCl 3) : 7.947(d, 1H, J=8Hz), 7.048(d, 1H, J=8Hz), 6.888(d, 1H, J=8Hz), 6.744(s, 1H), 6.613~6.553(m, 2H), 6.045~6.002(m, 1H), 6.649(d, 1H, J=10Hz), 5.387(dd, 1H, J=17.2, 1.2Hz), 5.288(d, 1H, J=10.4Hz), 5.242(s, 2H), 4.634~4.607(m, 4H), 2.646~2.608(m, 3H), 1.637~1.561(m, 2H), 1.430(s, 6H), 1.399~1.257(m, 2H), 0.929(t, 3H, J=7.2Hz) | |
13C-NMR (CDCl 3) : 195.613, 158.641, 154.545, 153.837, 151.300, 132.246, 131.194, 130.316, 129.780, 126.166, 122.222, 121.610, 118.970, 117.665, 114.427, 112.520, 112.091, 80.770, 75.476, 69.558, 61.660, 35.965, 33.050, 27.485, 22.293, 13.853 | ||
실시예 54 | 1H-NMR (CDCl 3) : 8.050(dd, 1H, J=8.8, 1.2Hz), 7.427~7.338(m, 5H), 7.042(dd, 1H, J=8, 0.8Hz), 6.650~6.549(m, 3H), 6.474(s, 1H), 5.665(d, 1H, J=8.4Hz), 5.219(s, 2H), 5.108(s, 2H), 4.653~4.607(m, 3H), 4.241(br, 1H), 1.427(s, 6H), 1.357(s, 3H), 1.342(s, 3H) | |
13C-NMR (CDCl 3) : 194.745, 164.444, 159.670, 154.967, 153.851, 135.907, 133.374, 130.156, 129.853, 128.717, 128.330, 127.485, 126.201, 118.540, 117.989, 114.223, 111.883, 106.602, 100.247, 80.878, 75.310, 70.847, 70.327, 61.766, 27.321, 21.994 | ||
실시예 55 | 1H-NMR (CDCl 3) : 7.824(d, 1H, J=8.8Hz), 7.663(d, 1H, J=8.4Hz), 7.272(s, 1H), 7.243(d, 1H, J=8Hz), 7.069(d, 1H, J=8Hz), 6.868(dd, 1H, J=8.8, 2.4Hz), 6.751(d, 1H, J=2.4Hz), 6.593(d, 1H, J=8.4Hz), 6.536(d, 1H, J=9.6Hz), 5.664(d, 1H, J=10Hz), 5.026(s, 2H), 4.562(s, 2H), 3.798(s, 3H), 3.15(br, 1H), 2.418(s, 3H), 1.427(s, 6H) | |
13C-NMR (CDCl 3) : 194, 163.926, 153.806, 153.609, 149.353, 146.301, 132.214, 131.516, 130.816, 130.029, 129.774, 128.309, 125.937, 122.075, 116.978, 114.564, 113.116, 112.464, 108.177, 79.077, 75.759, 61.093, 55.809, 27.550, 21.698 | ||
실시예 56 | 1H-NMR (CDCl 3) : 8.009(d, 1H, J=8Hz), 7.946(d, 1H, J=8Hz), 7.874(d, 1H, J=7.6Hz), 7.508~7.424(m, 4H), 7.016(s, 1H), 6.951(dd, 1H, J=8.4, 0.8Hz), 6.870(d, 1H, J=8Hz), 6.438(d, 1H, J=8.4Hz), 5.903(d, 1H, J=9.6Hz), 5.528(s, 2H), 5.155(d, 1H, J=10Hz), 4.883(s, 2H), 4.258(d, 2H, J=4.8Hz), 3.049(br, 1H), 2.672(t, 2H, J=7.6Hz), 1.733~1.676(m, 2H), 1.279(s, 6H), 0.983(t, 3H, J=7.2Hz) | |
- | ||
실시예 57 | 1H-NMR (CDCl 3) : 7.691(d, 1H, J=7.6Hz), 7.416~7.358(m, 5H), 7.267(d, 1H, J=9.2Hz), 7.156(s, 1H), 6.983(d, 1H, J=8.4Hz), 6.526(d, 1H, J=8Hz), 6.383(d, 1H, J=9.6Hz), 5.524(d, 1H, J=6.4Hz), 5.485(d, 1H, J=10Hz), 5.116(q, 2H, J=16, 11.2Hz), 4.619(d, 1H, J=11.6Hz), 4.464(d, 1H, J=11.6Hz), 4.233(dd, 1H, J=10., 2.4Hz), 3.859(q, 1H, J=10, 8.4Hz), 1.374(s, 3H), 1.356(s, 3H) | |
- | ||
실시예 58 | 1H-NMR (CDCl 3) : 8.028(d, 1H, J=8.8Hz), 6.584~6.557(m, 2H), 6.538~6.408(m, 2H), 6.071~6.002(m, 1H), 5.580(d, 1H, J=10Hz), 5.388(dd, 1H, J=17.2, 1.2Hz), 5.295(dd, 1H, J=10.8, 1.2Hz), 5.207(s, 2H), 4.723(d, 2H, J=3.6Hz), 4.583(d, 2H, J=5.6Hz), 3.963(t, 2H, J=6.8Hz), 3.669(br, 1H), 2.348(s, 3H), 1.844~1.792(m, 2H), 1.412(s, 6H), 1.040(t, 3H, J=7.6Hz) | |
13C-NMR (CDCl 3) : 194.441, 164.916, 160.332, 154.940, 153.077, 138.949, 133.145, 132.049, 129.089, 124.555, 119.021, 117.799, 117.648, 113.959, 111.768, 106.661, 99.312, 80.855, 75.354, 69.856, 69.581, 56.850, 27.465, 22.346, 19.329, 10.378 | ||
실시예 59 | 1H-NMR (CDCl 3) : 8.033(d, 1H, J=8Hz), 6.581~6.537(m, 2H), 6.458(s, 1H), 6.405(d, 1H, J=2Hz), 6.068~5.999(m, 1H), 5.583(d, 1H, J=10Hz), 5.389(dd, 1H, J=18.8, 1.2Hz), 5.296(dd, 1H, J=10.4, 1.2Hz), 5.208(s, 2H), 4.724(s, 2H), 4.579(d, 2H, J=5.6Hz), 4.079(q, 2H, J=14, 7.2Hz), 3.683(br, 1H), 2.350(s, 3H), 1.447~1.413(m, 9H) | |
13C-NMR (CDCl 3) : 194.467, 164.720, 160.332, 154.965, 153.107, 138.981, 133.213, 132.068, 129.121, 124.580, 119.055, 117.816, 117.761, 113.998, 111.799, 106.589, 99.403, 80.876, 75.388, 69.597, 63.949, 56.901, 27.497, 19.426, 14.592 | ||
실시예 60 | 1H-NMR (CDCl 3) : 7.997(dd, 1H, J=7.6, 1.6Hz), 7.529(t, 1H, J=8Hz), 7.088~7.004(m, 2H), 9.970(d, 1H, J=8.4Hz), 6.614(d, 1H, J=10Hz), 6.582(d, 1H, J=8.4Hz), 6.659(d, 1H, J=10Hz), 5.206(s, 2H), 4.606(s, 2H), 3.880(s, 3H), 3.306(br, 1H), 1.249(s, 6H) | |
- | ||
실시예 61 | 1H-NMR (CDCl 3) : 7.576(s, 1H), 7.504~7.324(m, 5H), 7.297(d, 1H, J=6.8Hz), 7.065(d, 1H, J=8Hz), 6.876(d, 1H, J=8.4Hz), 6.596(s, 1H), 6.574(s, 1H), 5.658(d, 1H, J=10Hz), 5.210(s, 2H), 5.174(s, 2H), 4.607(d, 2H, J=6Hz), 4.161(q, 2H, J=14, 6.8Hz), 3.165(t, 1H J=6Hz), 1.486(t, 3H, J=6.8Hz), 1.425(s, 6H) | |
13C-NMR (CDCl 3) : 193.041, 154.272, 153.906, 153.863, 148.440, 136.577, 130.902, 129.974, 128.511, 127.951, 127.345, 127.013, 125.968, 122.799, 116.971, 114.608, 113.354, 112.637, 111.670, 76.409, 75.779, 71.131, 64.582, 61.237, 27.637, 14.590 | ||
실시예 62 | 1H-NMR (CDCl 3) : 8.038(d, 1H, J=8Hz), 6.588(dd, 1H, J=8.8, 2.4Hz), 6.551(dd, 1H, J=9.6, 0.4Hz), 6.443(d, 1H, J=2Hz), 6.231(s, 1H), 6.068~5.988(m, 2H), 5.489(d, 1H, J=10Hz), 5.442~5.269(m, 4H), 5.193(s, 2H), 4.734(s, 2H), 4.593~4.572(m, 4H), 3.805(s, 3H), 3.3(br, 1H), 1.421(s, 6H) | |
13C-NMR (CDCl 3) : 193.834, 164.157, 160.240, 158.901, 155.163, 154.371, 133.163, 132.272, 132.061, 127.111, 118.970, 118.374, 118.132, 117.611, 114.862, 107.431, 106.790, 99.730, 95.984, 80.951, 76.020, 69.617, 69.048, 55.676, 54.620, 27.525 | ||
실시예 63 | 1H-NMR (CDCl 3) : 7.964(d, 1H, J=7.6Hz), 7.249(d, 1H, J=9.6Hz), 7.118(d, 2H, J=8Hz), 7.010(d, 1H, J=8Hz), 6.895(d, 1H, J=8Hz0, 6.842(s, 1H), 6.541(d, 1H, J=8Hz), 6.391(d, 1H, J=10Hz), 5.468(d, 1H, J=9.6Hz), 5.125(s, 2H), 5.070(s, 2H), 4.505(d, 2H, J=6.4Hz), 3.243(t, 1H, J=6.4Hz), 2.614(t, 2H, J=7.6Hz), 2.351(s, 3H), 1.681~1.603(m, 2H), 1.371(s, 6H), 0.941(t, 3H, J=7.6Hz) | |
- | ||
실시예 64 | 1H-NMR (CDCl 3) : 8.048(d, 1H, J=8Hz), 7.042(d, 1H, J=8.4Hz), 6.614~6.548(m, 3H), 6.449(d, 1H, J=2Hz), 6.067~5.995(m, 2H), 5.651(d, 1H, J=10Hz), 5.444~5.285(m, 4H), 5.216(s, 2H), 4.631(d, 2H, J=6.4Hz), 4.596~4.571(m, 4H), 3.964(t, 1H, J=6.8Hz), 1.430(s, 6H) | |
13C-NMR (CDCl 3) : 194.330, 164.317, 160.321, 154.619, 153.784, 133.201, 132.202, 131.945, 130.248, 129.739, 126.183, 119.170, 118.384, 117.872, 117.699, 114.379, 111.991, 106.869, 99.644, 80.651, 75.428, 69.640, 69.049, 61.670, 27.446 | ||
실시예 65 | 1H-NMR (CDCl 3) : 8.226(s, 1H), 7.356~7.340(m, 5H), 7.004(d, 1H, J=8Hz), 6.535(d, 1H, J=8.4Hz), 6.466(s, 1H), 6.391(d, 1H, J=10Hz), 5.589(d, 1H, J=10Hz), 5.140(s, 2H), 5.090(s, 2H), 4.503(s, 2H), 3.880(s, 3H), 3.304(br, 1H), 1.369(s, 6H) | |
13C-NMR (CDCl 3) : 192.960, 160.781, 159.785, 154.001, 153.726, 135.344, 134.899, 130.429, 129.713, 128.860, 128.773, 127.840, 126.024, 118.387, 117.098, 114.380, 112.214, 103.874, 96.809, 80.664, 75.542, 71.436, 61.290, 56.447, 27.550 | ||
실시예 66 | 1H-NMR (CDCl 3) : 8.153(s, 1H), 7.899~7.305(m, 5H), 7.101(d, 1H, J=8.4Hz), 6.902(s, 1H), 6.537(d, 1H, J=8.4Hz), 6.385(d, 1H, J=9.6Hz), 5.487(d, 1H, J=10Hz), 5.111(s, 4H), 4.479(s, 2H), 3.15(br, 1H), 2.741(q, 2H), 1.366(s, 6H), 1.213(t, 3H) | |
13C-NMR (CDCl 3) : 194.067, 157.790, 153.830, 153.714, 150.582, 135.130, 134.619, 130.479, 129.690, 128.744, 128.611, 127.874, 125.907, 123.793, 116.989, 115.933, 114.364, 113.804, 112.275, 80.706, 75.554, 71.223, 61.183, 29.899, 27.539, 13.716 | ||
실시예 67 | 1H-NMR (CDCl 3) : 7.979(d, 1H, J=8.8Hz), 7.022~6.970(m, 2H), 6.852(d, 1H, J=6.8Hz), 6.569(d, 1H, J=8.4Hz), 6.179(s, 1H), 5.183(s, 2H), 4.547(s, 2H), 3.704(t, 2H, J=6.8Hz), 3.1(br, 1H), 2.783(t, 2H, J=6.4Hz), 2.521(s, 6H), 2.325(s, 3H), 1.772~1.681(m, 4H), 1.325(s, 6H), 0.960(t, 3H, J=6.4Hz) | |
13C-NMR (CDCl 3) : 193.349, 163.498, 156.236, 154.929, 149.805, 144.620, 140.311, 132.573, 131.963, 130.804, 127.966, 124.781, 122.253, 114.952, 113.711, 113.148, 107.229, 77.984, 73.991, 70.016, 32.154, 26.639, 22.598, 22.074, 17.789, 10.197 | ||
실시예 68 | 1H-NMR (CDCl 3) : 7.875(d, 1H, J=8.8Hz), 7.640(d, 2H, J=8.4Hz), 7.223(d, 2H, J=8Hz), 7.042(d, 1H, J=8.4Hz), 6.890(d, 1H, J=2.8Hz), 6.703(s, 1H), 6.627(d, 1H, J=8.4Hz), 5.046(s, 2H), 4.546(s, 2H), 3.794(s, 3H), 3.1(br, 1H), 2.749(t, 2H, J=6.8Hz), 2.415(s, 3H), 1.741(t, 2H, J=6.4Hz), 1.332(s, 6H) | |
13C-NMR (CDCl 3) : 193.321, 163.945, 156.181, 154.994, 149.466, 147.364, 146.315, 132.356, 131.660, 130.052, 128.307, 128.143, 124.754, 122.182, 114.848, 113.260, 113.172, 108.098, 77.774, 74.030, 61.494, 55.824, 32.133, 26.675, 21.734, 17.811 |
Claims (5)
- (a) 화학식 1의 화합물을 환원시켜 화학식 2의 화합물을 제조하는 단계; 및(b) 상기 화학식 2의 화합물을 화학식 3의 화합물과 커플링시키는 단계를 포함하는 화학식 4로 표시되는 2-((6-(히드록시메틸)크로멘-5-일)옥시)-1-페닐에타논 유도체의 합성 방법:[반응식 1]상기 화학식들에서,점선은 선택적 이중결합이며;R 1 및 R 2는 각각 독립적으로 수소 원자; 치환 또는 비치환, 직쇄 또는 분지쇄 C 1-C 6 알킬기; 할로겐 원자; 치환 또는 비치환, 직쇄 또는 분지쇄 C 1-C 6 알콕시기; 치환 또는 비치환, 직쇄 또는 분지쇄 C 1-C 4 티오알킬기; 치환 또는 비치환 알릴옥시기; 치환 또는 비치환 아릴옥시기; 및 페닐기 중 어느 하나이고;R 3은 수소 원자; C 1-C 3 알킬기; C 1-C 3 알콕시기; 및 할로겐 원자 중 어느 하나이며;R 4 및 R 5는 각각 독립적으로 수소 원자; 또는 C 1-C 2 알킬기 중 어느 하나이고;P는 치환 또는 비치환, 직쇄 또는 분지쇄 C 1-C 4 알킬기; 치환 또는 비치환된 벤질기; 알릴기; t-부틸다이메틸실릴기; t-부틸다이페닐실릴기; 다이메틸페닐실릴기; 트리메틸실릴기; MeSO 2; p-톨루엔설포닐기; 및 2,4,6-트리메틸벤젠설포닐기 중 어느 하나이며;n은 1 내지 3이고;OP가 복수개일 때는 동일 또는 상이하며;상기 치환 알킬기, 치환 알콕시기, 치환 티오알킬기, 치환 알릴옥시기, 치환 아릴옥시기 및 치환 벤질기의 경우, 상기 치환기는 벤질옥시기, 할로겐 원자, 직쇄 또는 분지쇄 C 1-C 5 알킬기, 직쇄 또는 분지쇄 C 1-C 5 알콕시기, 직쇄 또는 분지쇄 C 1-C 3 티오알킬기, 니트로기 및 나프탈렌기 중 어느 하나이다.
- 제1항에 있어서,상기 (b) 단계는 염기 조건에서 이루어지는 것인 2-((6-(히드록시메틸)크로멘-5-일)옥시)-1-페닐에타논 유도체의 합성 방법.
- 제2항에 있어서,상기 염기 조건은 수산화나트륨(NaOH), 수산화칼륨(KOH), 탄산나트륨(Na 2CO 3), 탄산리튬(Li 2CO 3), 탄산칼륨(K 2CO 3), 탄산수소나트륨(NaHCO 3), 탄산수소칼륨(KHCO 3), 트리에틸아민 및 피리딘 중에서 선택된 1종 이상의 염기성 화합물의 첨가에 의한 것인 2-((6-(히드록시메틸)크로멘-5-일)옥시)-1-페닐에타논 유도체의 합성 방법.
- (i) 제1항 내지 제3항 중 어느 한 항에 따라 제조된 화학식 4의 화합물을 고리화시켜 화학식 5의 화합물을 제조하는 단계; 및(ii) 상기 화학식 5의 화합물을 환원시키는 단계를 포함하는 화학식 I의 3-페닐-2,3,4,8,9,10-헥사히드로피라노[2,3-f]크로멘 유도체의 합성 방법:[반응식 2]상기 화학식들에서,점선은 선택적 이중결합이며;R 1 및 R 2는 각각 독립적으로 수소 원자; 치환 또는 비치환, 직쇄 또는 분지쇄 C 1-C 6 알킬기; 할로겐 원자; 치환 또는 비치환, 직쇄 또는 분지쇄 C 1-C 6 알콕시기; 치환 또는 비치환, 직쇄 또는 분지쇄 C 1-C 4 티오알킬기; 치환 또는 비치환 알릴옥시기; 치환 또는 비치환 아릴옥시기; 및 페닐기 중 어느 하나이고;R 3은 수소 원자; C 1-C 3 알킬기; C 1-C 3 알콕시기; 및 할로겐 원자 중 어느 하나이며;R 4 및 R 5는 각각 독립적으로 수소 원자; 또는 C 1-C 2 알킬기 중 어느 하나이고;P는 치환 또는 비치환, 직쇄 또는 분지쇄 C 1-C 4 알킬기; 치환 또는 비치환된 벤질기; 알릴기; t-부틸다이메틸실릴기; t-부틸다이페닐실릴기; 다이메틸페닐실릴기; 트리메틸실릴기; MeSO 2; p-톨루엔설포닐기; 및 2,4,6-트리메틸벤젠설포닐기 중 어느 하나이며;n은 1 내지 3이고;OP가 복수개일 때는 동일 또는 상이하며;상기 치환 알킬기, 치환 알콕시기, 치환 티오알킬기, 치환 알릴옥시기, 치환 아릴옥시기 및 치환 벤질기의 경우, 상기 치환기는 벤질옥시기, 할로겐 원자, 직쇄 또는 분지쇄 C 1-C 5 알킬기, 직쇄 또는 분지쇄 C 1-C 5 알콕시기, 및 직쇄 또는 분지쇄 C 1-C 3 티오알킬기, 니트로기 및 나프탈렌기 중 어느 하나이다.
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112022001536A BR112022001536A2 (pt) | 2019-07-30 | 2020-07-20 | Método para sintetizar derivado de 2-((6-(hidroximetil)cromeno-5-il)óxi)-1-feniletanona |
HRP20230692TT HRP20230692T1 (hr) | 2019-07-30 | 2020-07-20 | Postupak sinteze derivata 2-((6-(hidroksimetil)hromen-5-il)oksi)-1-feniletanona |
CN202080055507.0A CN114206846B (zh) | 2019-07-30 | 2020-07-20 | 2-((6-(羟甲基)色烯-5-基)氧基)-1-苯基乙酮衍生物的合成方法 |
PL20846199.6T PL4006018T3 (pl) | 2019-07-30 | 2020-07-20 | Sposób syntezowania pochodnej 2-((6-(hydroksymetylo)chromen-5-ylo)oksy) -1-fenyloetanonu |
US17/630,985 US20220298170A1 (en) | 2019-07-30 | 2020-07-20 | Method for synthesizing 2-((6-(hydroxymethyl)chromene-5-yl)oxy)-1-phenylethanone derivative |
EP20846199.6A EP4006018B1 (en) | 2019-07-30 | 2020-07-20 | Method for synthesizing 2-((6-(hydroxymethyl)chromene-5-yl)oxy)-1-phenylethanone derivative |
AU2020321548A AU2020321548A1 (en) | 2019-07-30 | 2020-07-20 | Method for synthesizing 2-((6-(hydroxymethyl)chromene-5-yl)oxy)-1-phenylethanone derivative |
MX2022001103A MX2022001103A (es) | 2019-07-30 | 2020-07-20 | Metodo para sintetizar el derivado de 2-((6-(hidroximetil)cromeno- 5-il)oxi)-1-feniletanona. |
ES20846199T ES2949217T3 (es) | 2019-07-30 | 2020-07-20 | Método para sintetizar el derivado de 2-((6-(hidroximetil)cromen-5-il)oxi)-1-feniletanona |
JP2022506236A JP2022542993A (ja) | 2019-07-30 | 2020-07-20 | 2-((6-(ヒドロキシメチル)クロメン-5-イル)オキシ)-1-フェニルエタノン誘導体の合成方法 |
CA3146211A CA3146211A1 (en) | 2019-07-30 | 2020-07-20 | Method for synthesizing 2-((6-(hydroxymethyl)chromene-5-yl)oxy)-1-phenylethanone derivative |
IL290140A IL290140A (en) | 2019-07-30 | 2022-01-26 | A method for the synthesis of a derivative of 2-((6-(hydroxymethyl)chroman-5-yl)oxy)-1-phenylethanone |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0092711 | 2019-07-30 | ||
KR1020190092711A KR20210014521A (ko) | 2019-07-30 | 2019-07-30 | 2-((6-(히드록시메틸)크로멘-5-일)옥시)-1-페닐에타논 유도체의 합성 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2021020788A2 true WO2021020788A2 (ko) | 2021-02-04 |
WO2021020788A3 WO2021020788A3 (ko) | 2021-08-12 |
Family
ID=74230704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/009549 WO2021020788A2 (ko) | 2019-07-30 | 2020-07-20 | 2-((6-(히드록시메틸)크로멘-5-일)옥시)-1-페닐에타논 유도체의 합성 방법 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220298170A1 (ko) |
EP (1) | EP4006018B1 (ko) |
JP (1) | JP2022542993A (ko) |
KR (1) | KR20210014521A (ko) |
CN (1) | CN114206846B (ko) |
AU (1) | AU2020321548A1 (ko) |
BR (1) | BR112022001536A2 (ko) |
CA (1) | CA3146211A1 (ko) |
ES (1) | ES2949217T3 (ko) |
HR (1) | HRP20230692T1 (ko) |
HU (1) | HUE063544T2 (ko) |
IL (1) | IL290140A (ko) |
MX (1) | MX2022001103A (ko) |
PL (1) | PL4006018T3 (ko) |
WO (1) | WO2021020788A2 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150075030A (ko) | 2013-12-24 | 2015-07-02 | (주)이룸바이오테크놀러지 | 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 |
KR20180037584A (ko) | 2016-10-04 | 2018-04-12 | 주식회사 글라세움 | 3-페닐-2,3,4,8,9,10-헥사히드로피라노[2,3-f]크로멘 유도체 및 이의 광학 이성질체 합성 방법 |
KR20190092711A (ko) | 2018-01-31 | 2019-08-08 | 주식회사 스마트시티그리드 | 대기 환경 센서의 고장을 검출하기 위한 방법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1265651A (zh) * | 1997-07-03 | 2000-09-06 | 旭化成工业株式会社 | 新颖的具有饱和环的三环化合物及其药物组合物 |
JP2006008604A (ja) * | 2004-06-25 | 2006-01-12 | Kuraray Co Ltd | イソフラバン誘導体の製造方法 |
WO2007058480A1 (en) * | 2005-11-16 | 2007-05-24 | Md Bioalpha Co., Ltd. | Composition having effect on treatment and prevention of diseases syndrome treatment with glabridin |
CN103030647B (zh) * | 2013-01-16 | 2014-10-29 | 山东省分析测试中心 | 一种光甘草定的合成方法 |
-
2019
- 2019-07-30 KR KR1020190092711A patent/KR20210014521A/ko active Search and Examination
-
2020
- 2020-07-20 HR HRP20230692TT patent/HRP20230692T1/hr unknown
- 2020-07-20 CN CN202080055507.0A patent/CN114206846B/zh active Active
- 2020-07-20 WO PCT/KR2020/009549 patent/WO2021020788A2/ko unknown
- 2020-07-20 MX MX2022001103A patent/MX2022001103A/es unknown
- 2020-07-20 ES ES20846199T patent/ES2949217T3/es active Active
- 2020-07-20 PL PL20846199.6T patent/PL4006018T3/pl unknown
- 2020-07-20 AU AU2020321548A patent/AU2020321548A1/en active Pending
- 2020-07-20 US US17/630,985 patent/US20220298170A1/en active Pending
- 2020-07-20 CA CA3146211A patent/CA3146211A1/en active Pending
- 2020-07-20 EP EP20846199.6A patent/EP4006018B1/en active Active
- 2020-07-20 JP JP2022506236A patent/JP2022542993A/ja active Pending
- 2020-07-20 HU HUE20846199A patent/HUE063544T2/hu unknown
- 2020-07-20 BR BR112022001536A patent/BR112022001536A2/pt unknown
-
2022
- 2022-01-26 IL IL290140A patent/IL290140A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150075030A (ko) | 2013-12-24 | 2015-07-02 | (주)이룸바이오테크놀러지 | 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 |
KR20180037584A (ko) | 2016-10-04 | 2018-04-12 | 주식회사 글라세움 | 3-페닐-2,3,4,8,9,10-헥사히드로피라노[2,3-f]크로멘 유도체 및 이의 광학 이성질체 합성 방법 |
KR20190092711A (ko) | 2018-01-31 | 2019-08-08 | 주식회사 스마트시티그리드 | 대기 환경 센서의 고장을 검출하기 위한 방법 |
Also Published As
Publication number | Publication date |
---|---|
WO2021020788A3 (ko) | 2021-08-12 |
CN114206846B (zh) | 2024-05-28 |
PL4006018T3 (pl) | 2023-10-02 |
US20220298170A1 (en) | 2022-09-22 |
EP4006018C0 (en) | 2023-06-07 |
CA3146211A1 (en) | 2021-02-04 |
MX2022001103A (es) | 2022-05-10 |
JP2022542993A (ja) | 2022-10-07 |
EP4006018B1 (en) | 2023-06-07 |
EP4006018A2 (en) | 2022-06-01 |
KR20210014521A (ko) | 2021-02-09 |
ES2949217T3 (es) | 2023-09-26 |
HUE063544T2 (hu) | 2024-01-28 |
EP4006018A4 (en) | 2022-09-07 |
HRP20230692T1 (hr) | 2023-10-13 |
BR112022001536A2 (pt) | 2022-03-29 |
CN114206846A (zh) | 2022-03-18 |
AU2020321548A1 (en) | 2022-03-10 |
IL290140A (en) | 2022-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020145514A1 (ko) | L-글루포시네이트 제조 방법 | |
WO2011071314A2 (en) | Processes for preparing crystalline forms a and b of ilaprazole and process for converting the crystalline forms | |
WO2018008920A1 (ko) | 항종양 효과를 갖는 이미다조옥사졸 유도체 및 이를 포함하는 약학적 조성물 | |
WO2020149723A1 (ko) | 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2015102426A1 (en) | Novel indole derivative compound and pharmaceutical composition comprising the same | |
EP2611776A2 (en) | Production method of intermediate compound for synthesizing medicament | |
WO2014010990A1 (en) | Novel pyridine derivatives and method for preparation of intermediate compound for producing sulfonylurea herbicides using the same | |
WO2021020788A2 (ko) | 2-((6-(히드록시메틸)크로멘-5-일)옥시)-1-페닐에타논 유도체의 합성 방법 | |
WO2019066467A1 (ko) | (2r)-2-(2-메톡시페닐)-2-(옥산-4-일옥시)에탄-1-올 화합물의 신규 제조방법 및 이에 사용되는 중간체 | |
WO2010036000A2 (en) | Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof | |
WO2021066578A1 (ko) | 바이사이클릭 화합물 및 이의 용도 | |
WO2021118003A1 (ko) | 신규 혈관누출 차단제의 고수율 제조방법 | |
WO2022220612A1 (ko) | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법 | |
WO2023277658A1 (ko) | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 | |
WO2023101115A1 (ko) | 고순도의 1-(1-(2-벤질페녹시)프로판-2-일)-2-메틸피페리딘 단일 이성질체의 제조방법 | |
WO2014098410A1 (ko) | 보센탄 일수화물의 제조방법, 이에 사용되는 신규 중간체 및 이의 제조방법 | |
WO2021080380A1 (en) | Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity | |
WO2021172955A1 (ko) | Sglt 저해제의 합성에 유용한 중간체 및 이를 이용한 sglt 저해제의 제조 방법 | |
WO2019088800A2 (ko) | 폴리에틸렌글리콜 유도체 및 이의 제조방법 | |
WO2017090991A1 (ko) | 벤조피란 유도체의 정제방법, 이의 결정형 및 상기 결정형의 제조방법 | |
WO2023191379A1 (ko) | 3,4-다이하이드로퀴녹살린-2-카복사미드 유도체 화합물 및 이를 포함하는 암 질환 예방 또는 치료용 약학적 조성물 | |
WO2020009374A1 (ko) | 4-치환 옥사졸로퀴놀리논 유도체, 약학적으로 허용되는 이의 염인 화합물 및 이를 유효성분으로 포함하는 천식 또는 아토피 등의 알러지성 질환의 예방 또는 치료용 약학 조성물 | |
WO2022220608A1 (ko) | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법 | |
WO2022060114A1 (ko) | 퀴나졸린-2,4-다이아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2019107992A1 (ko) | P34 단백질 및 nedd4-1 단백질의 결합 억제제로서의 신규 화합물 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20846199 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2022506236 Country of ref document: JP Kind code of ref document: A Ref document number: 3146211 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022001536 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020846199 Country of ref document: EP Effective date: 20220228 |
|
ENP | Entry into the national phase |
Ref document number: 2020321548 Country of ref document: AU Date of ref document: 20200720 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112022001536 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220127 |